WO2006054738A1 - ミルベマイシン化合物およびアベルメクチン化合物の活性汚泥処理法 - Google Patents
ミルベマイシン化合物およびアベルメクチン化合物の活性汚泥処理法 Download PDFInfo
- Publication number
- WO2006054738A1 WO2006054738A1 PCT/JP2005/021329 JP2005021329W WO2006054738A1 WO 2006054738 A1 WO2006054738 A1 WO 2006054738A1 JP 2005021329 W JP2005021329 W JP 2005021329W WO 2006054738 A1 WO2006054738 A1 WO 2006054738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milbemycin
- compound
- activated sludge
- treatment
- milbemycins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F3/00—Biological treatment of water, waste water, or sewage
- C02F3/02—Aerobic processes
- C02F3/12—Activated sludge processes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/34—Nature of the water, waste water, sewage or sludge to be treated from industrial activities not provided for in groups C02F2103/12 - C02F2103/32
- C02F2103/343—Nature of the water, waste water, sewage or sludge to be treated from industrial activities not provided for in groups C02F2103/12 - C02F2103/32 from the pharmaceutical industry, e.g. containing antibiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W10/00—Technologies for wastewater treatment
- Y02W10/10—Biological treatment of water, waste water, or sewage
Definitions
- the present invention relates to biosynthesis of milbemycins and avermectins by microbial culture, and industrial wastewater produced by the production of pesticides and veterinary drugs from these. It is related with the method of using and processing. Background art
- Milbemycins and avermectins are 16-membered macrolide antibiotics produced by Streptomyces microorganisms and are known to have insecticidal, acaricidal and anthelmintic activity.
- Examples of milbemycins include the compounds shown in the following table.
- avermectins include abamectin, doramethatin, eprinomectin, and ivermectin.
- the production of these milbemycins and avermectins consists of culturing bacteria belonging to the genus Streptomyces, separating the cells from the culture medium, and then producing the produced milbemycins or avermectins using organic strength. After extraction with a solvent, the obtained substance containing the target compound is purified.
- various semi-synthetic milbemycin compounds and avermectin compounds are also synthesized.
- These filtrates and wastewater contain the power of produced milbemycins or avermectins, compounds derived from milbemycins or avermectins, or production intermediates, which makes fish highly toxic. Also, since BOD and COD are high, they cannot be discharged as actual wastewater.
- the culture filtrate after separation of the mill base hygromycin producing bacterium producing the mixture from the culture solution of the mill base mycin A3 and mill base mycin A4 is, 80 m 3 culture scale culture (titer 3500 g / ml)
- the milbemycin A3 / A4 mixture contains about 15-20ppm, its BOD is about 60,000 ⁇ : L 10, OOOppm, and its COD is about 50,000-100,000p pm is there.
- the above mixture of milbemycin A3 and milbemycin A4 has a LC of 0.004 p when contacted for 48 hours in a toxicity test for Sujebi (Palae mon paucidens).
- wastewater containing hazardous substances can be treated by incineration, extraction, adsorption, UV ozonolysis, alkali treatment, heat treatment, chemical or physical treatment, or activity.
- Treatment with sludge is known.
- the power running cost is high, where treatment by the incineration method is generally performed.
- chemical 'physics The treatment by the conventional method has a problem that the running cost is high and a new treatment facility is required.
- the treatment with activated sludge which is widely used for the treatment of industrial wastewater with relatively low running costs, includes milbemycin compound or avermectin compound contained in wastewater as described below.
- Activated fouling E is an Achromobacter, Alcaligenes, Bacillus ⁇ Bacterium, Corynebactenum, Flavobacterium, Micrococcus ⁇ Pseudomonas, and other fungi, $ It is one ecosystem that is composed.
- the bacteria that make up activated sludge dissolve in the water and decompose the organic matter that is generated, so the water that contains activated sludge is purified. For this reason, activated sludge is widely used for water purification and sewage treatment.
- Patent Document 1 Japanese Patent Laid-Open No. 50-29742
- Patent Document 2 Japanese Patent Laid-Open No. 55-131398
- Patent Document 3 Japanese Patent Laid-Open No. 56-32481
- Patent Document 4 JP-A-1-193270
- Patent Document 5 JP-A-60-142991
- Patent Document 6 Japanese Patent Laid-Open No. 4-305579
- Patent Document 7 JP-A-8-193085
- Patent Document 8 JP-A-8-208657
- Patent Document 9 JP-A-8-259570
- Patent Document 10 Japanese Unexamined Patent Publication No. 9143183
- Patent Document 11 Japanese Unexamined Patent Application Publication No. 2002-12595
- Patent Document 12 JP-A-7-16589
- the inventors of the present invention have efficiently and safely reduced milbemycins and avermectins-containing industrial wastewater, such as culture filtrates of milbemycins and avermectins, at a low running cost.
- milbemycin compounds such as culture filtrate of microorganisms that produce milbemycins and avermectins, or industrial wastewater containing avermectins compounds inhibits the activity of microorganisms contained in activated sludge.
- the activated sludge treatment cannot be directly performed because there is a risk of losing the sludge's activity, and the running cost is not necessarily low in order to overcome it, and the activated sludge is easily affected by temperature. In particular, they did not show sufficient treatment activity at low temperatures in winter!
- the present inventors have used activated sludge to directly treat milbemycin compounds and avermectin compound-containing factory wastewater such as culture filtrates of milbemycins and avermectins, so that they can be used at high temperatures from spring to autumn. As a result, it was discovered that wastewater can be efficiently treated even at low temperatures in winter, and that the above object can be achieved, and the present invention has been completed.
- the present invention relates to a milbemycin compound or avermectin by subjecting a factory wastewater containing at least one selected milbemycin compound and avermectin compound power to activated sludge treatment.
- the present invention relates to a method characterized by removing a compound. The invention's effect
- millbemycin compound or avermectin compound compound-containing factory wastewater can be efficiently and safely not only at high temperatures in spring to autumn but also at low temperatures in winter. Furthermore, it can process at a low running cost.
- the method of the present invention is described in literatures such as the above-mentioned patent documents 5 to 11 for the culture filtrate containing milbemycins or avermectins produced after the production of milbemycins or avermectins by microorganisms. It can also be used efficiently for the treatment of wastewater produced when producing pesticides and veterinary drugs derived from milbemycins and avermectins.
- FIG. 1 shows an example of the configuration of an apparatus for continuously treating millemycin compound or avermectin compound containing factory wastewater with activated sludge.
- the milbemycin compound and avermectin compound contained in the factory wastewater that can be treated by the method of the present invention include milbemycins and avermectins produced by microbial culture. Mention may be made of any milbemycins and avermethatins. Among them, milbemycins include milbemycins selected from the group consisting of milbemycin A3, milbemycin A4, milbemycin D, milbemycin ⁇ 11, and milbemycin a14. Milbemycin A3, milbemycin A4, and mixtures of milbemycin A3 and milbemycin A4 are preferred! /.
- avermectins examples include abamethatin, doramethatin, eprinomectin, and ivermectin.
- milbemycins and avermectins produced by microbial culture are more effective than milbemycins or avermectins, pesticides, compounds derived as animal drugs, or milbemycins or avermectins.
- R 1 represents hydrogen or —OCO—CH ⁇ C (CH 3); R 2 represents methyl,
- the factory wastewater is any wastewater as long as it contains at least one species selected from the group consisting of milbemycin and avermectins.
- a culture filtrate containing at least one selected from the group consisting of milbemycins and avermectins is a culture of Streptomyces having the ability to produce milbemycins or avermectins. It is a culture filtrate after removing the cake containing a microbial cell. This culture filtrate contains about 15-20 ppm milbemycins or avermectins under normal culture conditions. In addition, the BOD value of such a filtrate is about 60,000 to 110, OOOppm, and the COD value is about 50,000 to 100, OOOppm.
- wastewater produced when producing pesticides and veterinary drugs induced by milbemycins and avermectins is diluted to such an extent that it can be treated with activated sludge before being treated with activated sludge for the above reasons. It is necessary to keep it. If the concentration of the milbemycin compound or avermectin compound in the wastewater after dilution is in the range of 0.16 to 10.7 ppm, it can be efficiently treated. When the wastewater is directly treated with activated sludge, the concentration of the milbemycin compound and the avermectin compound is 0.3 ppm or less, and preferably 0.1 to 0.2 ppm.
- the activated sludge microorganisms used in the method of the present invention are not particularly limited, and activated sludge microorganisms generally used for wastewater treatment can be used.
- activated sludge microorganisms generally used for wastewater treatment can be used.
- microorganisms of Zoogloea ea Zoogloea ramigera etc.
- bphaerotilus natans Beggiatoa alba
- mitotic fungi such as ⁇ 3 ⁇ 4 Thioploca sp.
- the use concentration of the activated sludge varies depending on the concentration of the milbemycin compound or the avermectin compound contained in the wastewater after dilution, and the treatment temperature.
- This concentration is usually 4,000 to 16, OOOppm for wastewater such as filtrate after dilution, containing 0.1 to 0.2 ppm of milbemycin or avermectiny. It is possible, preferably 6,000 to 14, OOOppm, and more preferably 8,000 to 12, OOOppm. It should be noted that the treatment can be carried out efficiently even at a use concentration of 16,0 OOppm or more, but considering the economic efficiency, the value of 16,0 OOppm or less is appropriate.
- the treatment temperature of the present invention can usually be 5 ° C to 35 ° C, preferably 8 ° C to 30 ° C, and more preferably 10 ° C to 25 ° C.
- the treatment time (residence time) of the present invention is a force that varies depending on the treatment temperature. Usually, it is 5 to 48 hours, preferably 10 to 30 hours, and more preferably 16 to 24 hours. is there. Even when the usage time is 48 hours or more, considering the economic efficiency of efficient processing, 48 hours or less is appropriate.
- the treatment pH value of the present invention is pH 6 to 8, preferably pH 7.
- the dissolved oxygen amount is usually 0.1 ppm to saturated dissolved oxygen amount, and preferably 0.2 ppm to saturated dissolved oxygen amount.
- wastewater such as a culture filtrate containing 15-20 ppm of milbemycin compound or avermectin compound is diluted with miscellaneous wastewater about 75-200 times, and milbemycin
- concentration of the compound or avermectiny compound is 0.1 to 0.2 ppm.
- Diluted wastewater [normally 4,000-16, OOOppm (preferably ⁇ , 6, 00 0-12, OOOppm, more preferably 8, OOOppm) activated sludge, usually 5 ° C to 35 ° C (preferably 8 ° C to 30 ° C, more preferably 10 ° C to 25 ° C), usually 5 to 48 hours (preferably 16 to 24 hours, more preferably 20 to 24 hours), dissolved oxygen power Usually, it is carried out by shaking while blowing air so that it becomes 0.1 ppm to saturated dissolved oxygen content (preferably 0.2 ppm to saturated dissolved oxygen content).
- milbemycin compound or avermectin is used for continuous treatment.
- Dilute wastewater such as culture filtrate containing the compound with miscellaneous wastewater to bring the concentration of milbemycin or avermectiny into 0.1 to 0.2 ppm.
- the activated sludge treatment tank is filled with diluted wastewater, and the concentration of activated sludge in the diluted wastewater is usually 4,000 to 16, OOOppm (preferably 6,000 ppm to 14,000 ppm, more preferably 8 , 00 0-12, OOOppm), the activated sludge is stored in the activated sludge treatment tank, and the diluted wastewater is fed into the activated sludge treatment tank at an injection rate set to achieve a predetermined residence time. Inject continuously. Since the activated sludge treatment tank is aerated, the wastewater injected into the activated sludge treatment tank is agitated by the air sludge.
- OOOppm preferably 6,000 ppm to 14,000 ppm, more preferably 8 , 00 0-12, OOOppm
- Wastewater that has been treated for a predetermined time (residence time) passes through the lower part of the partition plate, overflows the activated sludge treatment tank, is discharged, and then sent to the contact oxidation treatment tank for further treatment. receive.
- the temperature is usually 5 ° C to 35 ° C (preferably 8 to 30 ° C, more preferably 20 ° C to 25 ° C in the spring to autumn season, and 8 ° in the winter season, depending on the temperature chamber. C-10 ° C).
- the treatment (residence) time is usually 5 to 48 hours (preferably 10 to 30 hours, more preferably 16 to 24 hours, particularly 16 to 20 hours in the spring to autumn season, and 20 to 24 in the winter season.
- the treatment (residence) time can be adjusted by adjusting the rate of injection of the diluted wastewater into the activated sludge treatment tank.
- Figure 1 shows an example of the equipment configuration for continuous processing.
- the feed water (1) which is the waste water after dilution, is sent to the active sludge treatment tank (3) by the pump (2), and in the activated sludge treatment tank (3). It stays for a certain period of time, where it is subjected to decomposition treatment with activated sludge under an aeration system to which air is supplied. Thereafter, the treated wastewater passes under the partition plate (6) and overflows, and is sent to the contact oxidation treatment tank.
- the activated sludge treatment tank (3) is placed in the thermostatic tank (7) and is kept at a constant temperature.
- the culture filtrate of milbemycin A3ZA4 was diluted with miscellaneous wastewater to adjust the concentration of milbemycin A3ZA4 to 0.16 ppm.
- the TOC value of the diluted solution was 747 ppm.
- the TOC value was measured by combustion-non-dispersive infrared gas analysis using a Shimadzu TOC meter (TOC-5000A).
- the treatment was repeated continuously for 1 week every day, and 100 ml of 0.34 ppm milbemycin A3ZA4-containing diluted solution was added to the separated activated sludge.
- the activated sludge treatment was performed under the same conditions as above. ⁇ , the concentration and TOC value of milbemycin A3ZA4 in the supernatant obtained by centrifuging the treatment liquid were measured, and from the obtained values, The removal rate was determined. This operation was repeated again every day for a week.
- the activated sludge treatment was performed under the same conditions as above for the diluted solution with a milbemycin A3ZA4 concentration of 0.16 ppm at a treatment temperature of 10 ° C! ⁇ , the concentration of milbemycin A3ZA4 in the supernatant after treatment And the TOC value was measured to determine the removal rate.
- Table 1 shows the average values of milbemycin A3ZA4 and TOC values before and after treatment, and the respective removal rates for each concentration before treatment.
- milbemycin A3ZA4 is biodegraded by activated sludge at low temperatures as well as at high temperatures without inhibiting the activity of activated sludge, and the treatment activity of milbemycin A3ZA4 by activated sludge was observed to increase by additional feed of milbemycin A3ZA4 during the treatment process.
- Example 2 The same activated sludge as in Example 1 was used.
- the activated sludge treatment tank (1.24L) was treated at an activated sludge concentration of 10 and OOOppm, and thereafter the activated sludge concentration was maintained at 10,000 to 12 and OOOppm.
- the injection rate of the feed water into the activated sludge treatment tank is 20 hours when the residence time in the activated sludge treatment tank is assumed to be spring-autumn (injection rate: 0.02 LZ hours), and 24 hours when the winter is assumed ( (Injection speed: 0.052 LZ time).
- the feed water is pumped to the activated sludge treatment tank at the above injection rate, adjusted to pH 7, and aerated by injecting air with an air pump so that the dissolved oxygen is 0.2 ppm or more. while doing Continuous activated sludge treatment was performed at a constant temperature. A small amount of sample is collected from the treated water after staying for a certain period of time, and the supernatant obtained by centrifugation is separated by decantation.
- the treatment was carried out at 20-25 ° C, the temperature corresponding to autumn, and 8-10 ° C, the temperature corresponding to winter.
- Table 3 and Table 4 show the milbemycin A3ZA4 concentration before and after treatment, the TOC value, and the average of the respective removal rates.
- Treatment temperature 20 to 25
- residence time 20 hours
- treatment period 1.5 power month
- Treatment temperature 8 ⁇ 10 t: Residence time: 24 hours, Treatment period: 1.5 power month
- Milbemycins were produced by microorganisms, and the produced milbemycins were used to produce agricultural chemicals and veterinary drugs. Dilute industrial wastewater containing agricultural chemicals and veterinary drugs and intermediates produced in the production of these products with miscellaneous wastewater, and dilute water containing 1 or lOppm of these compounds as a whole. Prepared. The chemical formulas of these compounds are shown below.
- Example 3 In place of the diluted wastewater containing the pesticides and veterinary drugs and intermediates of milbemycin A3ZA4 produced in Example 3, diluted wastewater containing 5-oxime-milbemycin A3ZA4 ⁇ m was used.
- the activated sludge treatment was performed for 24 hours under the same conditions as in Example 3. Thereafter, medaka was reared in the treated water under the same conditions as in Example 3. As a result, after 72 hours, it was confirmed that all medaka fish were alive.
- the BOD removal rate by activated sludge treatment was 95% or more.
- Milbemycin A3ZA4 in Example 3 Diluted wastewater containing 14 and 15 epoxy milbemycin A3ZA4 lOppm was used in place of the diluted wastewater containing the produced agricultural chemicals and veterinary drugs and their intermediates.
- the activated sludge was treated for 24 hours under the same conditions as in Example 3. Thereafter, medaka was reared in the treated water under the same conditions as in Example 3. As a result, after 72 hours, it was confirmed that all medaka fish were alive.
- the BOD removal rate by activated sludge treatment was 95% or more.
- milbemycin compounds such as culture filtrate produced after the production of milbemycins and avermectins by microorganisms or industrial wastewater containing avermectin compounds can be efficiently and It can be handled safely and at low running costs.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Hydrology & Water Resources (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Activated Sludge Processes (AREA)
- Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20050809741 EP1829828A1 (en) | 2004-11-22 | 2005-11-21 | Method of treating milbemycin compound and abermectin compound with active sludge |
JP2006545191A JPWO2006054738A1 (ja) | 2004-11-22 | 2005-11-21 | ミルベマイシン化合物およびアベルメクチン化合物の活性汚泥処理法 |
US11/719,673 US20090206033A1 (en) | 2004-11-22 | 2005-11-21 | Method for Treating Milbemycin Compounds and Avermectin Compounds with Active Sludge |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-337555 | 2004-11-22 | ||
JP2004337555 | 2004-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006054738A1 true WO2006054738A1 (ja) | 2006-05-26 |
Family
ID=36407271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/021329 WO2006054738A1 (ja) | 2004-11-22 | 2005-11-21 | ミルベマイシン化合物およびアベルメクチン化合物の活性汚泥処理法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090206033A1 (ja) |
EP (1) | EP1829828A1 (ja) |
JP (1) | JPWO2006054738A1 (ja) |
KR (1) | KR20070095910A (ja) |
TW (1) | TW200626511A (ja) |
WO (1) | WO2006054738A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101665817B (zh) * | 2009-09-28 | 2011-02-16 | 浙江升华拜克生物股份有限公司 | 阿维菌素发酵废水循环利用方法 |
CN114477471A (zh) * | 2022-02-16 | 2022-05-13 | 杭州秀川科技有限公司 | 一种复合菌群处理甲维盐胺化废水的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI126240B (en) * | 2011-12-02 | 2016-08-31 | Kemira Oyj | Method and apparatus for monitoring and controlling the state of the process |
CN113121066A (zh) * | 2021-04-23 | 2021-07-16 | 河北胜尔邦环保科技有限公司 | 一种阿维菌素废水的处理方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0716589A (ja) * | 1991-08-31 | 1995-01-20 | Nippon Arushii Kk | 活性汚泥処理法 |
JPH0970595A (ja) * | 1995-09-04 | 1997-03-18 | Kurita Water Ind Ltd | 活性汚泥処理系における固液分離障害抑制剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547491A (en) * | 1984-07-18 | 1985-10-15 | Merck & Co., Inc. | C-8A-Oxo-avermectin and milbemycin derivatives, pharmaceutical compositions and method of use |
GB2268930A (en) * | 1992-07-24 | 1994-01-26 | Chemfix Technologies Inc | Method of treating waste to make it suitable for ultimate disposal |
US20090092624A1 (en) * | 2007-08-17 | 2009-04-09 | Alberte Randall S | Antiinfective Flavononol Compounds and Methods of Use Thereof |
-
2005
- 2005-11-21 EP EP20050809741 patent/EP1829828A1/en not_active Withdrawn
- 2005-11-21 JP JP2006545191A patent/JPWO2006054738A1/ja not_active Withdrawn
- 2005-11-21 KR KR20077014121A patent/KR20070095910A/ko not_active Application Discontinuation
- 2005-11-21 WO PCT/JP2005/021329 patent/WO2006054738A1/ja active Application Filing
- 2005-11-21 TW TW094140792A patent/TW200626511A/zh unknown
- 2005-11-21 US US11/719,673 patent/US20090206033A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0716589A (ja) * | 1991-08-31 | 1995-01-20 | Nippon Arushii Kk | 活性汚泥処理法 |
JPH0970595A (ja) * | 1995-09-04 | 1997-03-18 | Kurita Water Ind Ltd | 活性汚泥処理系における固液分離障害抑制剤 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101665817B (zh) * | 2009-09-28 | 2011-02-16 | 浙江升华拜克生物股份有限公司 | 阿维菌素发酵废水循环利用方法 |
CN114477471A (zh) * | 2022-02-16 | 2022-05-13 | 杭州秀川科技有限公司 | 一种复合菌群处理甲维盐胺化废水的方法 |
CN114477471B (zh) * | 2022-02-16 | 2023-02-28 | 杭州秀川科技有限公司 | 一种复合菌群处理甲维盐胺化废水的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20070095910A (ko) | 2007-10-01 |
EP1829828A1 (en) | 2007-09-05 |
US20090206033A1 (en) | 2009-08-20 |
TW200626511A (en) | 2006-08-01 |
JPWO2006054738A1 (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | Fate and distribution of pharmaceutically active compounds in mesocosm constructed wetlands | |
Gorito et al. | Constructed wetland microcosms for the removal of organic micropollutants from freshwater aquaculture effluents | |
Christofilopoulos et al. | Evaluation of a constructed wetland for wastewater treatment: Addressing emerging organic contaminants and antibiotic resistant bacteria | |
Liu et al. | Fate of tetracycline in enhanced biological nutrient removal process | |
Wijekoon et al. | The fate of pharmaceuticals, steroid hormones, phytoestrogens, UV-filters and pesticides during MBR treatment | |
Pedersen et al. | Peracetic acid degradation and effects on nitrification in recirculating aquaculture systems | |
Semrany et al. | Bioaugmentation: possible solution in the treatment of bio-refractory organic compounds (Bio-ROCs) | |
Nzengung et al. | Plant-mediated transformation of perchlorate into chloride | |
Ansola et al. | Experimental and full–scale pilot plant constructed wetlands for municipal wastewaters treatment | |
Stasinakis et al. | Diuron biodegradation in activated sludge batch reactors under aerobic and anoxic conditions | |
McKinlay et al. | Observations on decontamination of herbicide-polluted water by marsh plant systems | |
Zheng et al. | Phytoremediation mechanisms and plant eco-physiological response to microorganic contaminants in integrated vertical-flow constructed wetlands | |
US9758409B2 (en) | Biological purifier for untreated waste water and method of producing the same, biological purification method for untreated waste water, and biological purification system for untreated waste water | |
Wilderer et al. | Impact of the addition of pure cultures on the performance of mixed culture reactors | |
Li et al. | Factors affecting the treatment of reject water by the anammox process | |
Zheng et al. | Stereoselective degradation pathway of amide chiral herbicides and its impacts on plant and bacterial communities in integrated vertical flow constructed wetlands | |
WO2006054738A1 (ja) | ミルベマイシン化合物およびアベルメクチン化合物の活性汚泥処理法 | |
Bôto et al. | Removing chemical and biological pollutants from swine wastewater through constructed wetlands aiming reclaimed water reuse | |
de Sousa Rollemberg et al. | Evaluation of sludge discharge methodologies in aerobic granular sludge reactors | |
Tempestti et al. | Detoxification of p-nitrophenol (PNP) using Enterococcus gallinarum JT-02 isolated from animal farm waste sludge | |
Kurzbaum et al. | Removal of phenol in a constructed wetland system and the relative contribution of plant roots, microbial activity and porous bed | |
Perotti et al. | Effect of diuron on aquatic bacteria in laboratory-scale wastewater treatment ponds with special reference to Aeromonas species studied by colony hybridization | |
Li et al. | Biological denitrification in high salinity wastewater using semen litchi as a carbon source | |
Mandelbaum et al. | Microbial degradation of s-triazine herbicides | |
Szczyrba et al. | Modelling of aerobic biodegradation of phenol by Stenotrophomonas maltophilia KB2 strain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006545191 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005809741 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077014121 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005809741 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11719673 Country of ref document: US |